CPE Scores Fail to Predict Neuropsychiatric Test Performance

Numerous studies have evaluated whether an antiretroviral's ability to penetrate into the central nervous system (CNS) can influence a patient's likelihood of developing neurocognitive disease. However, results have been conflicting, and the latest findings from the 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention only add to the mix [Rourke SB et al. Abstract MOAB0104].

Researchers conducted neuropsychiatric testing on 545 HIV-infected patients in Canada and categorized their antiviral regimens as having low or high CNS penetration effectiveness (CPE) scores (<2 vs. ≥2). They found no relationship between CPE score and neuropsychiatric test performance.